{
  "source": "PA-Notification-Mavenclad.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1349-6\nProgram Prior Authorization/Notification\nMedication Mavenclad® (cladribine)\nP&T Approval Date 1/2021, 1/2022, 1/2023, 1/2024, 1/2025, 4/2025\nEffective Date 7/1/2025\n1. Background:\nMavenclad® (cladribine) is indicated for the treatment of relapsing forms of multiple sclerosis\n(MS), to include relapsing-remitting disease and active secondary progressive disease, in adults.\nBecause of its safety profile, the use of Mavenclad is generally recommended for patients who\nhave had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the\ntreatment of MS. Mavenclad is not recommended for use in patients with clinically isolated\nsyndrome (CIS) because of its safety profile.1\nThe recommended cumulative dosage of Mavenclad is divided into 2 yearly treatment courses.\nEach treatment course is divided into 2 treatment cycles with the 2nd cycle administered 23-27\ndays after the last dose of the 1st cycle. Additional cycles of Mavenclad are not to be\nadministered after the completion of the 2nd treatment course. The safety and efficacy of\nreinitiating Mavenclad more than 2 years after completing 2 treatment courses has not been\nstudied.\n2. Coverage Criteriaa:\nA. Relapsing Forms of Multiple Sclerosis\n1. Initial Authorization\na. Mavenclad will be approved based on the following criterion:\n(1) Diagnosis of relapsing forms of multiple sclerosis (MS)\n-AND-\n(2) Patient has not already received the FDA-recommended limit of 2 lifetime treatment\ncourses (4 treatment cycles) of Mavenclad\nAuthorization will be issued for 2 months.\n2. Reauthorization\na. Mavenclad will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Mavenclad\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n1\n(2) Patient has not already received the FDA-recommended limit of 2 lifetime treatment\ncourses (4 treatment cycles) of Mavenclad\nAuthorization will be issued fo",
    " 2025 UnitedHealthcare Services, Inc.\n1\n(2) Patient has not already received the FDA-recommended limit of 2 lifetime treatment\ncourses (4 treatment cycles) of Mavenclad\nAuthorization will be issued for 2 months. (Duration of coverage will be limited to 1\nreauthorization to allow 2 cumulative treatment courses [4 treatment cycles] of\nMavenclad therapy.)\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits and/or Step Therapy may be in place.\n4. References:\n1. Mavenclad [package insert]. Rockland, MA: EMD Serono, Inc.; May 2024.\nProgram Prior Authorization/Notification – Mavenclad (cladribine)\nChange Control\n1/2021 New program.\n1/2022 Annual review with no change to clinical criteria.\n1/2023 Annual review. Added state mandate footnote. Updated reference.\n1/2024 Annual review with no change to clinical criteria.\n1/2025 Annual review with no change to clinical criteria. Updated reference.\n4/2025 Added statement to initial criteria “Patient has not already received the FDA-\nrecommended limit of 2 lifetime treatment courses (4 treatment cycles) of\nMavenclad” and revised similar statement in reauthorization criteria to\nclarify maximum recommended lifetime treatment.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}